Hodson R. Alzheimer’s disease. Nature. 2018;559:S1 https://doi.org/10.1038/d41586-018-05717-6

Article  CAS  PubMed  Google Scholar 

Huang LK, Kuan YC, Lin HW, Hu CJ. Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update. J Biomed Sci. 2023;30:83 https://doi.org/10.1186/s12929-023-00976-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sang Z, Wang K, Dong J, Tang L. Alzheimer’s disease: updated multi-targets therapeutics are in clinical and in progress. Eur J Med Chem. 2022;238:114464 https://doi.org/10.1016/j.ejmech.2022.114464

Article  CAS  PubMed  Google Scholar 

Saxena M, Dubey R. Target enzyme in Alzheimer’s disease: acetylcholinesterase inhibitors. Curr Top Med Chem. 2019;19:264–75. https://doi.org/10.2174/1568026619666190128125912

Article  CAS  PubMed  Google Scholar 

Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. Lecanemab, aducanumab, and gantenerumab—binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease. Neurotherapeutics. 2023;20:195–206. https://doi.org/10.1007/s13311-022-01308-6

Article  CAS  PubMed  Google Scholar 

Qiao Y, Chi Y, Zhang Q, Ma Y. Safety and efficacy of lecanemab for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. Front Aging Neurosci. 2023;15:1169499 https://doi.org/10.3389/fnagi.2023.1169499

Article  CAS  PubMed  PubMed Central  Google Scholar 

McHardy SF, Wang HL, McCowen SV, Valdez MC. Recent advances in acetylcholinesterase inhibitors and reactivators: an update on the patent literature (2012–2015). Expert Opin Ther Pat. 2017;27:455–76. https://doi.org/10.1080/13543776.2017.1272571

Article  CAS  PubMed  Google Scholar 

Desai AK, Grossberg GT. Rivastigmine for Alzheimer’s disease. Expert Rev Neurother. 2005;5:563–80. https://doi.org/10.1586/14737175.5.5.563

Article  CAS  PubMed  Google Scholar 

Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer’s disease. J Alzheimers Dis. 2013;35:349–61. https://doi.org/10.3233/JAD-122140

Article  CAS  PubMed  Google Scholar 

Desai A, Grossberg G. Review of rivastigmine and its clinical applications in Alzheimer’s disease and related disorders. Expert Opin Pharmacother. 2001;2:653–66. https://doi.org/10.1517/14656566.2.4.653

Article  CAS  PubMed  Google Scholar 

Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41:615–31. https://doi.org/10.3233/JAD-132690

Article  CAS  PubMed  Google Scholar 

Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. Int J Geriatr Psychiatry. 2006;21:17–28. https://doi.org/10.1002/gps.1402

Article  CAS  PubMed  Google Scholar 

Matošević A, Bosak A. Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents. Arh Hig Rada Toksikol. 2020;71:285–99. https://doi.org/10.2478/aiht-2020-71-3466

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kabir MT, Uddin MS, Begum MM, Thangapandiyan S, Rahman MS, Aleya L, et al. Cholinesterase inhibitors for Alzheimer’s disease: Multitargeting strategy based on anti-Alzheimer’s drugs repositioning. Curr Pharm Des. 2019;25:3519–35. https://doi.org/10.2174/1381612825666191008103141

Article  CAS  PubMed  Google Scholar 

Sang Z, Wang K, Shi J, Cheng X, Zhu G, Wei R, et al. Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer’s disease. Eur J Med Chem. 2020;187:111958 https://doi.org/10.1016/j.ejmech.2019.111958

Article  CAS  PubMed  Google Scholar 

Sang Z, Bai P, Ban Y, Wang K, Wu A, Mi J, et al. Novel donepezil-chalcone-rivastigmine hybrids as potential multifunctional anti-Alzheimer’s agents: Design, synthesis, in vitro biological evaluation, in vivo and in silico studies. Bioorg Chem. 2022;127:106007 https://doi.org/10.1016/j.bioorg.2022.106007

Article  CAS  PubMed  Google Scholar 

Gillis EP, Eastman KJ, Hill MD, Donnelly DJ, Meanwell NA. Applications of fluorine in medicinal chemistry. J Med Chem. 2015;58:8315–59. https://doi.org/10.1021/acs.jmedchem.5b00258

Article  CAS  PubMed  Google Scholar 

Meanwell NA. Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design. J Med Chem. 2018;61:5822–80. https://doi.org/10.1021/acs.jmedchem.7b01788

Article  CAS  PubMed  Google Scholar 

Wang BC, Wang LJ, Jiang B, Wang SY, Wu N, Li XQ, et al. Application of fluorine in drug design during 2010-2015 years: A Mini-Review. Mini Rev Med Chem. 2017;17:683–92. https://doi.org/10.2174/1389557515666151016124957

Article  CAS  PubMed  Google Scholar 

Sang Z, Wang K, Shi J, Liu W, Cheng X, Zhu G, et al. The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer’s disease. Eur J Med Chem. 2020;192:112180 https://doi.org/10.1016/j.ejmech.2020.112180

Article  CAS  PubMed  Google Scholar 

Sang Z, Wang K, Bai P, Wu A, Shi J, Liu W, et al. Tan Z. Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer’s disease. Eur J Med Chem. 2020;194:112265 https://doi.org/10.1016/j.ejmech.2020.112265

Article  CAS  PubMed  Google Scholar 

Yue L, Zhao L, Liu H, Li X, Wang B, Guo H, et al. Adiponectin protects against glutamate-induced excitotoxicity via activating SIRT1-dependent PGC-1α expression in HT22 hippocampal neurons. Oxid Med Cell Longev. 2016;2016:2957354 https://doi.org/10.1155/2016/2957354

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mi J, He Y, Yang J, Zhou Y, Zhu G, Wu A, et al. Development of naringenin-O-carbamate derivatives as multi-target-directed liagnds for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett. 2022;60:128574 https://doi.org/10.1016/j.bmcl.2022.128574

Article  CAS  PubMed  Google Scholar 

Sang Z, Wang K, Zhang P, Shi J, Liu W, Tan Z. Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer’s disease. Eur J Med Chem. 2019;180:238–52. https://doi.org/10.1016/j.ejmech.2019.07.021

Article  CAS  PubMed  Google Scholar